Publications

2024

Structure–function of type I and III interferons

de Weerd N. A., Kurowska A. K., Mendoza J. L. & Schreiber G. (2024) Current Opinion in Immunology. 86, 102413.

Harnessing the power of IFN for therapeutic approaches to COVID-19

G. V. E., E. B. S., C. D. D., Gideon S. & Mirko P. (2024) Journal of Virology. 98, 5, e01204-23.

2023

Characterization of the evolutionary and virological aspects of mutations in the receptor binding motif of the SARS-CoV-2 spike protein

Masuda Y., Nasser H., Zahradnik J., Mitoma S., Shimizu R., Nagata K., Takaori-Kondo A., Schreiber G., Shirakawa K., Saito A., Ikeda T., Ito J. & Sato K. (2023) Frontiers in Virology. 3, 1328229.

Enhanced transmissibility, infectivity, and immune resistance of the SARS-CoV-2 omicron XBB.1.5 variant

Uriu K., Ito J., Zahradnik J., Fujita S., Kosugi Y., Schreiber G. & Sato K. (2023) The Lancet Infectious Diseases. 23, 3, p. 280-281

Modulation of type I interferon responses potently inhibits SARS-CoV-2 replication and inflammation in rhesus macaques

Viox E. G., Hoang T. N., Upadhyay A. A., Nchioua R., Hirschenberger M., Strongin Z., Tharp G. K., Pino M., Nguyen K., Harper J. L., Gagne M., Marciano S., Boddapati A. K., Pellegrini K. L., Pradhan A., Tisoncik-Go J., Whitmore L. S., Karunakaran K. A., Roy M., Kirejczyk S., Curran E. H., Wallace C., Wood J. S., Connor-Stroud F., Voigt E. A., Monaco C. M., Gordon D. E., Kasturi S. P., Levit R. D., Gale M., Vanderford T. H., Silvestri G., Busman-Sahay K., Estes J. D., Vaccari M., Douek D. C., Sparrer K. M., Johnson R. P., Kirchhoff F., Schreiber G., Bosinger S. E. & Paiardini M. (2023) Science immunology. 8, 85, adg0033.

Paradoxical activation of chronic lymphocytic leukemia cells by ruxolitinib in vitro and in vivo

Spaner D. E., Luo T. Y. X., Wang G., Schreiber G., Harari D. & Shi Y. (2023) Frontiers in Oncology. 13, 1043694.

Virological characteristics of the SARS-CoV-2 XBB variant derived from recombination of two Omicron subvariants

Tamura T., Ito J., Uriu K., Zahradnik J., Kida I., Anraku Y., Nasser H., Shofa M., Oda Y., Lytras S., Nao N., Itakura Y., Deguchi S., Suzuki R., Wang L., Begum M. M., Kita S., Yajima H., Sasaki J. & Schreiber G. (2023) Nature Communications. 14, 1, 2800.

Convergent evolution of SARS-CoV-2 Omicron subvariants leading to the emergence of BQ.1.1 variant

Ito J., Suzuki R., Uriu K., Itakura Y., Zahradnik J., Kimura K. T., Deguchi S., Wang L., Lytras S., Tamura T., Kida I., Nasser H., Shofa M., Begum M. M., Tsuda M., Oda Y., Suzuki T., Sasaki J., Sasaki-Tabata K. & Schreiber G. (2023) Nature Communications. 14, 1, 2671.

Multiple mutations of SARS-CoV-2 Omicron BA.2 variant orchestrate its virological characteristics

Kimura I., Yamasoba D., Nasser H., Ito H., Zahradnik J., Wu J., Fujita S., Uriu K., Sasaki J., Tamura T., Suzuki R., Deguchi S., Plianchaisuk A., Yoshimatsu K., Kazuma Y., Mitoma S., Schreiber G., Asakura H., Nagashima M., Sadamasu K., Yoshimura K., Takaori-Kondo A., Ito J., Shirakawa K., Takayama K., Irie T., Hashiguchi T., Nakagawa S., Fukuhara T., Saito A., Ikeda T. & Sato K. (2023) Journal of Virology. 97, 10,

2022

Perspectives: SARS-CoV-2 Spike Convergent Evolution as a Guide to Explore Adaptive Advantage

Zahradník J., Nunvar J. & Schreiber G. (2022) Frontiers in Cellular and Infection Microbiology. 12, 748948.

In vitro Evolution of Uracil Glycosylase Towards DnaKJ and GroEL Binding Evolves Different Misfolded States

Melanker O., Goloubinoff P. & Schreiber G. (2022) Journal of Molecular Biology. 434, 13, 167627.

Virological characteristics of the SARS-CoV-2 Omicron BA.2 spike

Yamasoba D., Kimura I., Nasser H., Morioka Y. & Schreiber G. (2022) Cell. 185, 12, p. 2103-2115

Diffusion of small molecule drugs is affected by surface interactions and crowder proteins

Dey D., Nunes-Alves A., Wade R. C. & Schreiber G. (2022) iScience. 25, 10, 105088.

The SARS-CoV-2 spike S375F mutation characterizes the Omicron BA.1 variant

Kimura I., Yamasoba D., Nasser H., Zahradnik J. & Schreiber G. (2022) iScience. 25, 12, 105720.

Genetically Engineered MRI-Trackable Extracellular Vesicles as SARS-CoV-2 Mimetics for Mapping ACE2 Binding in Vivo

Galisova A., Zahradnik J., Allouche-Arnon H., Morandi M. I., Abou Karam P., Fisler M., Avinoam O., Regev-Rudzki N., Schreiber G. & Bar-Shir A. (2022) ACS Nano. 16, 8, p. 12276-12289

Gelatin Stabilizes Nebulized Proteins in Pulmonary Drug Delivery against COVID-19

Li C., Marton I., Harari D., Shemesh M., Kalchenko V., Pardo M., Schreiber G. & Rudich Y. (2022) ACS Biomaterials Science and Engineering. 8, 6, p. 2553-2563

SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses

Dejnirattisai W., Huo J., Khan S., Avinoam O. & Schreiber G. (2022) Cell. 185, 3, p. 467-484.e15

Protein quaternary structures in solution are a mixture of multiple forms

Marciano S., Dey D., Listov D., Fleishman S. J., Sonn-Segev A., Mertens H., Busch F., Kim Y., Harvey S. R., Wysocki V. H. & Schreiber G. (2022) Chemical Science. 13, 39, p. 11680-11695

2021

SARS-CoV-2 spike L452R variant evades cellular immunity and increases infectivity

Motozono C., Toyoda M., Zahradnik J., Saito A. & Schreiber G. (2021) Cell Host & Microbe. 29, 7, p. 1124-1136.e11

A Protein-Engineered, Enhanced Yeast Display Platform for Rapid Evolution of Challenging Targets

Zahradnik J., Dey D., Marciano S., Kolarova L., Charendoff C., Subtil A. & Schreiber G. (2021) ACS Synthetic Biology. 10, 12, p. 3445-3460

IFNAR1 and IFNAR2 play distinct roles in initiating type I interferon–induced JAK-STAT signaling and activating STATs

Shemesh M., Lochte S., Piehler J. & Schreiber G. (2021) Science Signaling. 14, 710, p. eabe4627-eabe4627

De novo developed protein binders mimicking Interferon lambda signaling

Kolářová L., Zahradník J., Huličiak M., Mikulecký P., Peleg Y., Shemesh M., Schreiber G. & Schneider B. (2021) The FEBS journal. 289, 9, p. 2672-2684

The SARS-CoV-2 Lambda variant exhibits enhanced infectivity and immune resistance

Kimura I., Kosugi Y., Wu J., Zahradnik J., Yamasoba D., Butlertanaka E. P., Tanaka Y. L., Uriu K., Liu Y., Morizako N., Shirakawa K., Kazuma Y., Nomura R., Horisawa Y., Tokunaga K., Ueno T., Takaori-Kondo A., Schreiber G., Arase H., Saito A., Motozono C., Nakagawa S. & Sato K. (2021) Cell reports (Cambridge). 38, 2, p. 110218-

Line-FRAP, A Versatile Method to Measure Diffusion Rates In Vitro and In Vivo

Dey D., Marciano S., Nunes-Alves A., Kiss V., Wade R. C. & Schreiber G. (2021) Journal of Molecular Biology. 433, 9, 166898.

SARS-CoV-2 suppresses IFN[beta] production mediated by NSP1, 5, 6, 15, ORF6 and ORF7b but does not suppress the effects of added interferon

Shemesh M., Aktepe T. E., Deerain J. M., McAuley J. L., Audsley M. D., David C. T., Purcell D. F. J., Urin V., Hartmann R., Moseley G. W., Mackenzie J. M., Schreiber G. & Harari D. (2021) PLoS Pathogens. 17, 8, e1009800.

SARS-CoV-2 variant prediction and antiviral drug design are enabled by RBD in vitro evolution

Zahradník J., Marciano S., Shemesh M., Zoler E., Harari D., Chiaravalli J., Meyer B., Rudich Y., Li C., Marton I., Dym O., Elad N., Lewis M., Andersen H., Gagne M., Seder R., Douek D. & Schreiber G. (2021) Nature Microbiology. 6, 9, p. 1188-1198

2019

Dose-Dependent Differences in HIV Inhibition by Different Interferon Alpha Subtypes While Having Overall Similar Biologic Effects

Schlaepfer E., Fahrny A., Gruenbach M., Kuster S. P., Simon V., Schreiber G. & Speck R. F. (2019) mSphere. 4, 1, e00637-18.

CRISPR/Cas9-based Knockout Strategy Elucidates Components Essential for Type 1 Interferon Signaling in Human HeLa Cells

Urin V., Shemesh M. & Schreiber G. (2019) Journal of Molecular Biology. 431, 17, p. 3324-3338

Reply to Hasenkrug et al., "Different Biological Activities of Specific Interferon Alpha Subtypes"

Schlaepfer E., Fahrny A., Gruenbach M., Kuster S. P., Simon V., Schreiber G. & Speck R. F. (2019) mSphere. 4, 4, e00275-19.

Competing Ligands Can Both Obstruct and Enhance Protein-Complex Formation

Schreiber G. (2019) Biophysical Journal. 117, 9, p. 1552-1553

2018

Selecting for Fast Protein-Protein Association As Demonstrated on a Random TEM1 Yeast Library Binding BLIP

Cohen-Khait R. & Schreiber G. (2018) Biochemistry. 57, 31, p. 4644-4650

Type I IFN signaling blockade by a PASylated antagonist during chronic SIV infection suppresses specific inflammatory pathways but does not alter T cell activation or virus replication

Nganou-Makamdop K., Billingsley J. M., Yaffe Z., O'Connor G., Tharp G. K., Ransier A., Laboune F., Matus-Nicodemos R., Lerner A., Gharu L., Robertson J. M., Ford M. L., Schlapschy M., Kuhn N., Lensch A., Lifson J., Nason M., Skerra A., Schreiber G., Bosinger S. E. & Douek D. C. (2018) PLoS Pathogens. 14, 8, 1007246.

Human-Specific Adaptations in Vpu Conferring Anti-tetherin Activity Are Critical for Efficient Early HIV-1 Replication In Vivo

Yamada E., Nakaoka S., Klein L., Reith E., Langer S., Hopfensperger K., Iwami S., Schreiber G., Kirchhoff F., Koyanagi Y., Sauter D. & Sato K. (2018) Cell Host and Microbe. 23, 1, p. 110-120

2017

Direct determination of enzyme kinetic parameters from single reactions using a new progress curve analysis tool

Baeuerle F., Zotter A. & Schreiber G. (2017) Protein Engineering, Design and Selection. 30, 3, p. 151-158

Dynamic Modulation of Binding Affinity as a Mechanism for Regulating Interferon Signaling

Li H., Sharma N., General I. J., Schreiber G. & Bahar I. (2017) Journal of Molecular Biology. 429, 16, p. 2571-2589

Quantifying enzyme activity in living cells

Zotter A., Baeuerle F., Dey D., Kiss V. & Schreiber G. (2017) Journal of Biological Chemistry. 292, 38, p. 15838-15848

Promiscuous Protein Binding as a Function of Protein Stability

Cohen-Khait R., Dym O., Hamer-Rogotner S. & Schreiber G. (2017) Structure (London, England : 1993). 25, 12, p. 1867-1874.e3

The molecular basis for differential type i interferon signaling

Schreiber G. (2017) Journal of Biological Chemistry. 292, 18, p. 7285-7294

2016

Type I Interferon Signaling Is Decoupled from Specific Receptor Orientation through Lenient Requirements of the Transmembrane Domain

Sharma N., Longjam G. & Schreiber G. (2016) Journal of Biological Chemistry. 291, 7, p. 3371-3384

Low-stringency selection of TEM1 for BLIP shows interface plasticity and selection for faster binders

Cohen-Khait R. & Schreiber G. (2016) Proceedings of the National Academy of Sciences of the United States of America. 113, 52, p. 14982-14987

2015

The molecular basis for functional plasticity in type I interferon signaling

Schreiber G. & Piehler J. (2015) Trends in Immunology. 36, 3, p. 139-149

Fine tuning of a type 1 interferon antagonist

Urin V., Levin D., Sharma N., Harari D. & Schreiber G. (2015) PLoS ONE. 10, 7, e0130797.

A robust type I interferon gene signature fromblood RNA defines quantitative but not qualitative differences between three major IFNβ drugs in the treatment of multiple sclerosis

Harari D., Orr I., Rotkopf R., Baranzini S. & Schreiber G. (2015) Human Molecular Genetics. 24, 11, p. 3192-3205

2014

Type i interferon responses in rhesus macaques prevent SIV infection and slow disease progression

Sandler N. G., Bosinger S. E., Estes J. D., Zhu R. T., Tharp G. K., Boritz E., Levin D., Wijeyesinghe S., Makamdop K. N., Del Prete G. Q., Hill B. J., Timmer J. K., Reiss E., Yarden G., Darko S., Contijoch E., Todd J. P., Silvestri G., Nason M., Norgren R. B., Keele B. F., Rao S., Langer J. A., Lifson J. D., Schreiber G. & Douek D. C. (2014) Nature. 511, 7511, p. 601-605

Multifaceted activities of type I interferon are revealed by a receptor antagonist

Levin D., Schneider W. M., Hoffmann H., Yarden G., Busetto A. G., Manor O., Sharma N., Rice C. M. & Schreiber G. (2014) Science Signaling. 7, 327, ra50.

Science Signaling Podcast: 27 May 2014

Schreiber G. & VanHook A. M. (2014) Science Signaling. 7, 327, pc14.

Bridging the species divide: Transgenic mice humanized for type-I interferon response

Harari D., Abramovich R., Zozulya A., Smith P., Pouly S., Koester M., Hauser H. & Schreiber G. (2014) PLoS ONE. 9, 1, e84259.

PyInteraph: A framework for the analysis of interaction networks in structural ensembles of proteins

Tiberti M., Invernizzi G., Lambrughi M., Inbar Y., Schreiber G. & Papaleo E. (2014) Journal of Chemical Information and Modeling. 54, 5, p. 1537-1551

Enhanced in vivo efficacy of a type I interferon superagonist with extended plasma half-life in a mouse model of multiple sclerosis

Harari D., Kuhn N., Abramovich R., Sasson K., Zozulya A. L., Smith P., Schlapschy M., Aharoni R., Koester M., Eilam R., Skerra A. & Schreiber G. (2014) Journal of Biological Chemistry. 289, 42, p. 29014-29029

Editorial overview: Folding and binding

Bardwell J. & Schreiber G. (2014) Current Opinion in Structural Biology. 24, p. VIII-X

Enhanced in vivo efficacy of a long-life type I Interferon superagonist in a mouse model of multiple sclerosis

Harari D., Kallweit N., Abramovich R., Sasson K., Zozulya A., Smith P., Schlapschy M., Aharoni R., Koester M., Eliam R., Skerra A. & Schreiber G. (2014) Journal of Neuroimmunology. 275, 2-Jan, p. 219-219

Enhanced in vivo efficacy using a novel long-life type I interferon variant in a mouse model of multiple sclerosis

Harari D., Kallweit N., Abramovich R., Sasson K., Zozulya A., Smith P., Schlapschy M., Aharoni R., Koester M., Eliam R., Skerra A. & Schreiber G. (2014) Cytokine. 70, 1, p. 45-45

2013

Formation of protein complexes in crowded environments-From in vitro to in vivo

Phillip Y. & Schreiber G. (2013) FEBS Letters. 587, 8, p. 1046-1052

Type I interferons induce apoptosis by balancing cFLIP and caspase-8 independent of death ligands

Apelbaum A., Yarden G., Warszawski S., Harari D. & Schreiber G. (2013) Molecular and Cellular Biology. 33, 4, p. 800-814

Computational design of protein-protein interactions

Schreiber G. & Fleishman S. J. (2013) Current Opinion in Structural Biology. 23, 6, p. 903-910

Microscale thermophoresis quantifies biomolecular interactions under previously challenging conditions

Seidel S. A., Dijkman P. M., Lea W. A., van den Bogaart G., Jerabek-Willemsen M., Lazic A., Joseph J. S., Srinivasan P., Baaske P., Simeonov A., Katritch I., Melo F. A., Ladbury J. E., Schreiber G., Watts A., Braun D. & Duhr S. (2013) Methods. 59, 3, p. 301-315

A novel type I interferon antagonist has in vivo efficacy in a model of SIV infection in rhesus macaques

Sandler N. G., Zhu R. T., Estes J. D., Boritz E., Rao S., Lifson J. D., Levin D., Schreiber G., Langer J. A. & Douek D. C. (2013) Cytokine. 63, 3, p. 296-296

Type I interferon signaling is suppressed in Experimental Autoimmune Encephalomyelitis (EAE): Implications for multiple sclerosis

Harari D., Abramovich R., Kallweit N., Pouly S., Zozulya-Weidenfeller A., Smith P., Schlapschy M., Koester M., Hauser H., Skerra A. & Schreiber G. (2013) Cytokine. 63, 3, p. 269-270

2012

Protein-binding dynamics imaged in a living cell

Phillip Y., Kiss V. & Schreiber G. (2012) Proceedings of the National Academy of Sciences of the United States of America. 109, 5, p. 1461-1466

Structural and dynamic determinants of type I interferon receptor assembly and their functional interpretation

Piehler J., Thomas C., Christopher Garcia K. & Schreiber G. (2012) Immunological Reviews. 250, 1, p. 317-334

FRETex: A FRET-based, high-throughput technique to analyze protein-protein interactions

Khait R. & Schreiber G. (2012) PROTEIN ENGINEERING DESIGN & SELECTION. 25, 11, p. 681-687

Contrasting factors on the kinetic path to protein complex formation diminish the effects of crowding agents

Phillip Y., Harel M., Khait R., Qin S., Zhou H. & Schreiber G. (2012) Biophysical Journal. 103, 5, p. 1011-1019

2011

Protein binding specificity versus promiscuity

Schreiber G. & Keating A. E. (2011) Current Opinion in Structural Biology. 21, 1, p. 50-61

Binding and activity of all human alpha interferon subtypes

Lavoie T. B., Kalie E., Crisafulli-Cabatu S., Abramovich R., DiGioia G., Moolchan K., Pestka S. & Schreiber G. (2011) Cytokine. 56, 2, p. 282-289

Stochastic receptor expression determines cell fate upon interferon treatment

Levin D., Harari D. & Schreiber G. (2011) Molecular and Cellular Biology. 31, 16, p. 3252-3266

Structural linkage between ligand discrimination and receptor activation by Type i interferons

Thomas C., Moraga I., Levin D., Krutzik P. O., Podoplelova Y., Trejo A., Lee C., Yarden G., Vleck S. E., Glenn J. S., Nolan G. P., Piehler J., Schreiber G. & Garcia K. C. (2011) Cell. 146, 4, p. 621-632

A quantitative, real-time assessment of binding of peptides and proteins to gold surfaces

Cohavi O., Reichmann D., Abramovich R., Tesler A. B., Bellapadrona G., Kokh D. B., Wade R. C., Vaskevich A., Rubinstein I. & Schreiber G. (2011) Chemistry-A European Journal. 17, 4, p. 1327-1336

Community-wide assessment of protein-interface modeling suggests improvements to design methodology

Fleishman S. J., Whitehead T. A., Strauch E., Corn J. E., Qin S., Zhou H., Mitchell J. C., Demerdash O. N. A., Takeda-Shitaka M., Terashi G., Moal I. H., Li X., Bates P. A., Zacharias M., Park H., Ko J., Lee H., Seok C., Bourquard T., Bernauer J., Poupon A., Aze J., Soner S., Ovali S. K., Ozbek P., Ben Tal N., Haliloglu T., Hwang H., Vreven T., Pierce B. G., Weng Z., Perez-Cano L., Pons C., Fernandez-Recio J., Jiang F., Yang F., Gong X., Cao L., Xu X., Liu B., Wang P., Li C., Wang C., Robert C. H., Guharoy M., Liu S., Huang Y., Li L., Guo D., Chen Y., Xiao Y., London N., Itzhaki Z., Schueler-Furman O., Inbar Y., Potapov V., Cohen M., Schreiber G., Tsuchiya Y., Kanamori E., Standley D. M., Nakamura H., Kinoshita K., Driggers C. M., Hall R. G., Morgan J. L., Hsu V. L., Zhan J., Yang Y., Zhou Y., Kastritis P. L., Bonvin A. M. J. J., Zhang W., Camacho C. J., Kilambi K. P., Sircar A., Gray J. J., Ohue M., Uchikoga N., Matsuzaki Y., Ishida T., Akiyama Y., Khashan R., Bush S., Fouches D., Tropsha A., Esquivel-Rodriguez J., Kihara D., Stranges P. B., Jacak R., Kuhlman B., Huang S., Zou X., Wodak S. J., Janin J. & Baker D. (2011) Journal of Molecular Biology. 414, 2, p. 289-302

2010

Cytokine-receptor interactions as drug targets

Schreiber G. & Walter M. R. (2010) Current Opinion in Chemical Biology. 14, 4, p. 511-519

A comparison of the binding of Interferon alpha subtypes to isolated IFNAR1 and IFNAR2 with activity in antiviral and antiproliferative assays

Lavoie T. B., Abramovich R., Cabatu S. C., DiGioia G., Moolchan K., Pestka S. & Schreiber G. (2010) Cytokine. 52, 2-Jan, p. 86-86

Protein-surface interactions: Challenging experiments and computations

Cohavi O., Corni S., De Rienzo R. F., Di Felice F. R., Gottschalk K. E., Hoefling M., Kokh D., Molinari E., Schreiber G., Vaskevich A. & Wade R. C. (2010) Journal of Molecular Recognition. 23, 3, p. 259-262

Protein structure modelling and evaluation based on a 4-distance description of side-chain interactions

Potapov V., Cohen M., Inbar Y. & Schreiber G. (2010) BMC Bioinformatics. 11, 374.

2009

Receptor density is key to the alpha2/beta interferon differential activities

Moraga I., Harari D., Schreiber G., Uzé G. & Pellegrini S. (2009) Molecular and Cellular Biology. 29, 17, p. 4778-4787

Common crowding agents have only a small effect on protein-protein interactions

Phillip Y., Sherman E., Haran G. & Schreiber G. (2009) Biophysical Journal. 97, 3, p. 875-885

Fruitful and futile encounters along the association reaction between proteins

Harel M., Spaar A. & Schreiber G. (2009) Biophysical Journal. 96, 10, p. 4237-4248

Understanding hydrogen-bond patterns in proteins using network motifs

Rahat O., Alon U., Levy Y. & Schreiber G. (2009) Bioinformatics. 25, 22, p. 2921-2928

Fundamental aspects of protein - Protein association kinetics

Schreiber G., Haran G. & Zhou H. (2009) Chemical Reviews. 109, 3, p. 839-860

Designer interferons reveal the relation between receptor binding and differential biological activity

Schreiber G., Harari D., Kalie E. & Jaitin D. A. (2009) Cytokine. 48, 2-Jan, p. 121-121

Four distances between pairs of amino acids provide a precise description of their interaction

Cohen M., Potapov V. & Schreiber G. (2009) PLoS Computational Biology. 5, 8, e1000470.

Assessing computational methods for predicting protein stability upon mutation: Good on average but not in the details

Potapov V., Cohen M. & Schreiber G. (2009) PROTEIN ENGINEERING DESIGN & SELECTION. 22, 9, p. 553-560

Improved binding of Raf to Ras·GDP is correlated with biological activity

Kiel C., Filchtinski D., Spoerner M., Schreiber G., Kalbitzer H. R. & Herrmann C. (2009) Journal of Biological Chemistry. 284, 46, p. 31893-31902

Docking of Antizyme to Ornithine Decarboxylase and Antizyme Inhibitor using Experimental Mutant and Double-Mutant Cycle Data

Cohavi O., Tobi D. & Schreiber G. (2009) Journal of Molecular Biology. 390, 3, p. 503-515

2008

Mutation of the IFNAR-1 receptor binding site of human IFN-α2 generates type I IFN competitive antagonists

Pan M., Kalie E., Scaglione B. J., Raveche E. S., Schreiber G. & Langer J. A. (2008) Biochemistry. 47, 46, p. 12018-12027

Cluster conservation as a novel tool for studying protein-protein interactions evolution

Rahat O., Yitzhaky A. & Schreiber G. (2008) Proteins-Structure Function And Bioinformatics. 71, 2, p. 621-630

On the contribution of water-mediated interactions to protein-complex stability

Reichmann D., Phillip Y., Carmi A. & Schreiber G. (2008) Biochemistry. 47, 3, p. 1051-1060

The stability of the ternary interferon-receptor complex rather than the affinity to the individual subunits dictates differential biological activities

Kalie E., Jaitin D. A., Podoplelova Y., Piehler J. & Schreiber G. (2008) Journal of Biological Chemistry. 283, 47, p. 32925-32936

The ProteOn XPR36 (TM) Array System-High Throughput Kinetic Binding Analysis of Biomolecular Interactions

Bravman T., Bronner V., Nahshol O. & Schreiber G. (2008) Cellular and Molecular Bioengineering. 1, 4, p. 216-228

Similar chemistry, but different bond preferences in inter versus intra-protein interactions

Cohen M., Reichmann D., Neuvirth H. & Schreiber G. (2008) Proteins-Structure Function And Bioinformatics. 72, 2, p. 741-753

Computational Redesign of a Protein-Protein Interface for High Affinity and Binding Specificity Using Modular Architecture and Naturally Occurring Template Fragments

Potapov V., Reichmann D., Abramovich R., Filchtinski D., Zohar N., Ben Halevy H. D., Edelman M., Sobolev V. & Schreiber G. (2008) Journal of Molecular Biology. 384, 1, p. 109-119

2007

The fast release of sticky protons: Kinetics of substrate binding and proton release in a multidrug transporter

Adam Y., Tayer N., Rotem D., Schreiber G. & Schuldiner S. (2007) Proceedings of the National Academy of Sciences of the United States of America. 104, 46, p. 17989-17994

On the Dynamic Nature of the Transition State for Protein-Protein Association as Determined by Double-mutant Cycle Analysis and Simulation

Harel M., Cohen M. & Schreiber G. (2007) Journal of Molecular Biology. 371, 1, p. 180-196

Noncovalent, site-specific biotinylation of histidine-tagged proteins

Reichel A., Schaible D., Al Furoukh F. N., Cohen M., Schreiber G. & Piehler J. (2007) Analytical Chemistry. 79, 22, p. 8590-8600

Binding Hot Spots in the TEM1-BLIP Interface in Light of its Modular Architecture

Reichmann D., Cohen M., Abramovich R., Dym O., Lim D., Strynadka N. C. J. & Schreiber G. (2007) Journal of Molecular Biology. 365, 3, p. 663-679

Upregulation of a small subset of genes drives type I interferon-induced antiviral memory

Jaitin D. A. & Schreiber G. (2007) Journal of Interferon and Cytokine Research. 27, 8, p. 653-664

An interferon α2 mutant optimized by phage display for IFNAR1 binding confers specifically enhanced antitumor activities

Kalie E., Jaitin D. A., Abramovich R. & Schreiber G. (2007) Journal of Biological Chemistry. 282, 15, p. 11602-11611

Protein-protein association in polymer solutions: From dilute to semidilute to concentrated

Kozer N., Kuttner Y. Y., Haran G. & Schreiber G. (2007) Biophysical Journal. 92, 6, p. 2139-2149

The receptor of the type I interferon family

Uze G., Schreiber G., Piehler J. & Pellegrini S. (2007) Interferon: The 50Th Anniversary. 316, p. 71-95

Rediscovering secondary structures as network motifs - An unsupervised learning approach

Raveh B., Basri R. & Schreiber G. (2007) Bioinformatics. 23, 2, p. e163-e169

ProMateus: an open research approach to protein-binding sites analysis

Neuvirth H., Heinemann U., Birnbaum D., Tishby N. & Schreiber G. (2007) Nucleic Acids Research. 35, suppl 2, p. W543-W548

eMovie: a storyboard-based tool for making molecular movies

Hodis E., Schreiber G., Rother K. & Sussman J. L. (2007) Trends in Biochemical Sciences. 32, 5, p. 199-204

The molecular architecture of protein-protein binding sites

Reichmann D., Rahat O., Cohen M., Neuvirth H. & Schreiber G. (2007) Current Opinion in Structural Biology. 17, 1, p. 67-76

2006

Inquiring into the differential action of interferons (IFNs): An IFN-α2 mutant with enhanced affinity to IFNAR1 Is functionally similar to IFN-β

Jaitin D., Roisman L., Jaks E., Gavutis M., Pichler J., Van der Heyden d. H. J., Uze G. & Schreiber G. (2006) Molecular and Cellular Biology. 26, 5, p. 1888-1897

Binding characteristics of IFN-α subvariants to IFNAR2-EC and influence of the 6-histidine tag

Schmeisser H., Kontsek P., Esposito D., Gillette W., Schreiber G. & Zoon K. C. (2006) Journal of Interferon and Cytokine Research. 26, 12, p. 866-876

Variations in the Unstructured C-terminal Tail of Interferons Contribute to Differential Receptor Binding and Biological Activity

Slutzki M., Jaitin D. A., Ben-Yehezkel T. & Schreiber G. (2006) Journal of Molecular Biology. 360, 5, p. 1019-1030

2005

Three-dimensional structure determination of proteins related to human health in their functional context at the Israel Structural Proteomics Center (ISPC)

Albeck S., Burstein Y., Dym O., Jacobovitch Y., Levi N., Meged R., Michael Y., Peleg Y., Prilusky J., Schreiber G., Silman I., Unger T. & Sussman J. (2005) Acta Crystallographica Section D: Biological Crystallography. 61, 10, p. 1364-1372

The modular architecture of protein-protein binding interfaces

Reichmann D., Rahat O., Albeck S., Meged R., Dym O. & Schreiber G. (2005) Proceedings of the National Academy of Sciences of the United States of America. 102, 1, p. 57-62

Mutational analysis of the IFNAR1 binding site on IFNα2 reveals the architecture of a weak ligand-receptor binding-site

Roisman L., Jaitin D., Baker D. & Schreiber G. (2005) Journal of Molecular Biology. 353, 2, p. 271-281

The nitty-gritty of protein interactions

Schreiber G. (2005) Structure. 13, 12, p. 1737-1738

Folding and binding: an extended family business - Editorial overview

Schreiber G. & Serrano L. (2005) Current Opinion in Structural Biology. 15, 1, p. 1-3

Exploring the charge space of protein-protein association: A proteomic study

Shaul Y. & Schreiber G. (2005) Proteins-Structure Function And Bioinformatics. 60, 3, p. 341-352

Separating the contribution of translational and rotational diffusion to protein association

Kuttner Y., Kozer N., Segal E., Schreiber G. & Haran G. (2005) Journal of the American Chemical Society. 127, 43, p. 15138-15144

2004

ProMate: A structure based prediction program to identify the location of protein-protein binding sites

Neuvirth H., Raz R. & Schreiber G. (2004) Journal of Molecular Biology. 338, 1, p. 181-199

A novel method for scoring of docked protein complexes using predicted protein-protein binding sites

Gottschalk K., Neuvirth H. & Schreiber G. (2004) PROTEIN ENGINEERING DESIGN & SELECTION. 17, 2, p. 183-189

Optimizing the binding affinity of a carrier protein: A case study on the interaction between soluble ifnar2 and interferon β

Peleg-Shulman T., Roisman L., Zupkovitz G. & Schreiber G. (2004) Journal of Biological Chemistry. 279, 17, p. 18046-18053

Reversible PEGylation: A novel technology to release native interferon α2 over a prolonged time period

Peleg-Shulman T., Tsubery H., Mironchik M., Fridkin M., Schreiber G. & Shechter Y. (2004) Journal of Medicinal Chemistry. 47, 20, p. 4897-4904

Electrostatically optimized Ras-binding Ral guanine dissociation stimulator mutants increase the rate of association by stabilizing the encounter complex

Kiel C., Selzer T., Shaul Y., Schreiber G. & Herrmann C. (2004) Proceedings of the National Academy of Sciences of the United States of America. 101, 25, p. 9223-9228

Effect of Crowding on Protein-Protein Association Rates: Fundamental Differences between Low and High Mass Crowding Agents

Kozer N. & Schreiber G. (2004) Journal of Molecular Biology. 336, 3, p. 763-774

2003

Free Energy Landscapes in Protein-Protein Interactions

Piehler J. & Schreiber G. (2003) Handbook of Cell Signaling. 1-3, p. 27-31

The human type I interferon receptor: NMR structure reveals the molecular basis of ligand binding

Chill J., Quadt S., Levy R., Schreiber G. & Anglister J. (2003) Structure. 11, 7, p. 791-802

2002

Kinetic studies of protein-protein interactions

Schreiber G. (2002) Current Opinion in Structural Biology. 12, 1, p. 41-47

The human interferon receptor: NMR-based modeling, mapping of the IFN-α2 binding site, and observed ligand-induced tightening

Chill J., Nivasch R., Levy R., Albeck S., Schreiber G. & Anglister J. (2002) Biochemistry. 41, 11, p. 3575-3585

2001

Fast transient cytokine-receptor interactions monitored in real time by reflectometric interference spectroscopy

Piehler J. & Schreiber G. (2001) Analytical Biochemistry. 289, 2, p. 173-186

Structure of the interferon-receptor complex determined by distance constraints from double-mutant cycles and flexible docking

Roisman L., Piehler J., Trosset J., Scheraga H. & Schreiber G. (2001) Proceedings of the National Academy of Sciences of the United States of America. 98, 23, p. 13231-13236

New insights into the mechanism of protein-protein association

Selzer T. & Schreiber G. (2001) Proteins-Structure Function And Genetics. 45, 3, p. 190-198

Prolonging the half-life of human interferon-α2 in circulation: Design, preparation, and analysis of (2-sulfo-9-fluorenylmethoxycarbonyl)7interferon-α2

Shechter Y., Preciado-Patt L., Schreiber G. & Fridkin M. (2001) Proceedings of the National Academy of Sciences of the United States of America. 98, 3, p. 1212-1217

Experimental assignment of the structure of the transition state for the association of barnase and barstar

Frisch C., Fersht A. R. & Schreiber G. (2001) Journal of Molecular Biology. 308, 1, p. 69-77

2000

New structural and functional aspects of the type I interferon-receptor interaction revealed by comprehensive mutational analysis of the binding interface

Piehler J., Roisman L. & Schreiber G. (2000) Journal of Biological Chemistry. 275, 51, p. 40425-40433

Evaluation of direct and cooperative contributions towards the strength of buried hydrogen bonds and salt bridges

Albeck S., Unger R. & Schreiber G. (2000) Journal of Molecular Biology. 298, 3, p. 503-520

Rational design of faster associating and tighter binding protein complexes

Selzer T., Albeck S. & Schreiber G. (2000) Nature Structural Biology. 7, 7, p. 537-541

1999

Biophysical analysis of the interaction of human ifnar2 expressed in E. coli with IFNα2

Piehler J. & Schreiber G. (1999) Journal of Molecular Biology. 289, 1, p. 57-67

Mutational and structural analysis of the binding interface between type I interferons and their receptor ifnar2

Piehler J. & Schreiber G. (1999) Journal of Molecular Biology. 294, 1, p. 223-237

Predicting the rate enhancement of protein complex formation from the electrostatic energy of interaction

Selzer T. & Schreiber G. (1999) Journal of Molecular Biology. 287, 2, p. 409-419

1998

Electrostatic enhancement of diffusion-controlled protein-protein association: Comparison of theory and experiment on barnase and barstar

Vijayakumar M., Wong K., Schreiber G., Fersht A., Szabo A. & Zhou H. (1998) Journal of Molecular Biology. 278, 5, p. 1015-1024

1997

The role of Glu73 of Barnase in catalysis and the binding of Barstar

Schreiber G., Frisch C. & Fersht A. R. (1997) Journal of Molecular Biology. 270, 1, p. 111-122

1996

Rapid, electrostatically assisted association of proteins

Schreiber G. & Fersht A. R. (1996) Nature Structural Biology. 3, 5, p. 427-431